Related Experiment Video
Updated: Sep 19, 2025
Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
Statins as potential adjuvant therapy in lung cancer: a narrative review
Ye Tian1, Jinbao Li1, Xueying Yang1
1Department of Thoracic Surgery, Fourth Affiliated Hospital of China Medical University, Shenyang, China.
Background And Objective:
Lung cancer is the leading cause of cancer-related deaths worldwide. Despite significant advances in lung cancer treatment, many patients respond poorly to existing standard treatments and are prone to developing drug resistance. Therefore, there is an urgent need to develop new pharmacological interventions. As a potential adjuvant therapy, statins have shown promise in the treatment of lung cancer. These drugs inhibit the mevalonate pathway, suppressing tumor cell growth and metastasis, inducing apoptosis, and enhancing the efficacy of anti-lung cancer drugs. This review aims to evaluate the role of statins in lung cancer treatment and explore their potential in combination with standard therapies.
Methods:
A comprehensive literature search was conducted to identify studies on the use of statins in lung cancer treatment, including their application in combination with standard therapies and their molecular mechanisms in inhibiting lung cancer. The search encompassed multiple databases, including PubMed, Web of Science, and Google Scholar databases. Relevant articles were selected based on their titles, abstracts, and keywords, and the final selection was made according to the study's relevance and quality.
Key Content And Findings:
Statins have shown potential in lung cancer treatment, inhibiting tumor cell growth and metastasis, inducing apoptosis, and enhancing the efficacy of anti-lung cancer drugs. The combination of statins with standard treatments has been found to improve treatment outcomes and exhibit synergistic effects in some cases. However, clinical trial results have been inconsistent, and further research is needed to determine the role of statins in lung cancer treatment. Additionally, the study found that the effects of statins differ depending on the type and stage of lung cancer, and that lipophilic statins are more effective than hydrophilic statins.
Conclusions:
Statins have shown promise in lung cancer treatment, and their combination with standard treatments may be an effective strategy to improve treatment outcomes. However, further large-scale randomized controlled trials are needed to confirm the safety and efficacy of statins in lung cancer treatment, as well as in determining the optimal dosage and treatment regimen. This will provide the best possible treatment outcomes for lung cancer patients.
Insights
Statins show promise as an adjuvant therapy for lung cancer, inhibiting tumor growth and enhancing drug efficacy. Further research is needed to confirm their role in combination with standard treatments for improved patient outcomes.
Area of Science:
- Oncology
- Pharmacology
- Cancer Research
Background:
- Lung cancer remains a leading cause of cancer mortality globally.
- Existing treatments face challenges with poor patient response and drug resistance.
- Novel pharmacological interventions are crucial for improving lung cancer therapy.
Purpose of the Study:
- To evaluate the role of statins as an adjuvant therapy in lung cancer treatment.
- To explore the potential of statins in combination with standard lung cancer therapies.
- To review the molecular mechanisms by which statins affect lung cancer.
Main Methods:
- A comprehensive literature search was performed across major scientific databases (PubMed, Web of Science, Google Scholar).
- Articles were selected based on relevance and quality, focusing on statins in lung cancer treatment and their mechanisms.
- Studies investigating combination therapies and molecular actions were prioritized.
Main Results:
- Statins demonstrate potential in inhibiting lung cancer cell growth, metastasis, and inducing apoptosis.
- Combining statins with standard treatments may improve outcomes and show synergistic effects.
- Lipophilic statins appear more effective than hydrophilic statins, with effects varying by cancer type and stage.
Conclusions:
- Statins show promise as an adjunct to standard lung cancer treatments.
- Further large-scale randomized controlled trials are necessary to establish optimal dosage and regimens.
- Confirming the safety and efficacy of statins is essential for improving lung cancer patient outcomes.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:26Atherosclerosis III: Management
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...